Craig-Hallum lowered the firm’s price target on Champions Oncology to $9 from $10 and keeps a Buy rating on the shares. The firm says Q2 represents more of the same as cancellations weigh on results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CSBR:
